跳至主要内容
临床试验/NCT04364828
NCT04364828已完成不适用

NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression

University Hospital Tuebingen2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2020年10月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,000
试验地点
2
主要终点
Viral evolution

研究概览

简要总结

In this study (i) the host genome to identify susceptibility regions of infection, inflammation, and host defense, (ii) host response to Severe Acute Respiratory Syndrome-Corona-Virus-2 (SARS-CoV-2) infection, and (iii) viral sequence composition to define viral sequences which may be correlated with disease severity in addition to the metagenome of the throat swab will be analysed .

详细描述

This study aims to recruit adult persons with diagnostically confirmed Corona-Virus- Disease-19 (COVID-19) infection and with different disease manifestation who are included into diagnostic or therapeutic care at the University Hospital Tübingen (UKT).

The COVID-19 Next-Generation-Sequencing (NGS) study aims to cover as many patients in Germany as possible. It is expected to include in Phase 1 (pilot study): 250 patients with different disease manifestation (extreme phenotypes) and individual risk factors by whole genome analysis Phase 2 (verification study): 1.000 clinically well-defined patients to ensure a broader range of overlapping phenotypes, to verify data from the pilot study.

Phase 3 (confirmation study): > 10.000 patients to increase the power (anticipated).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Sequential
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COVID-19 infection confirmed
  • COVID-19 disease manifestation
  • Age > 18 years

排除标准

  • Missing informed consent of the patient/ legal guardian/ relatives

结局指标

主要结局

Viral evolution

时间窗: Day 1, Day 3-5, Day 7-9, 48 hours after recovery

The change in the genetic makeup of a virus population (measured in numbers) as the viruses mutate and multiply over time at different time points

次要结局

  • Immune response(Day 1, Day 3-5, Day 7-9, 48 hours after recovery)
  • Disease severity(Day 1, Day 3-5, Day 7-9, 48 hours after recovery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

NGS Diagnostic in COVID-19 Hosts - Genetic Cause... | 临床试验